Morgan Stanley’s Scinai Immunotherapeutics SCNI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15 | Hold |
6
| – | – | ﹤0.01% | 8317 |
|
|
2026
Q1 | $33 | Hold |
6
| – | – | ﹤0.01% | 8073 |
|
|
2025
Q4 | $41 | Sell |
6
-19
| -76% | -$217 | ﹤0.01% | 7924 |
|
|
2025
Q3 | $310 | Sell |
25
-1
| -4% | -$17 | ﹤0.01% | 7553 |
|
|
2025
Q2 | $581 | Hold |
26
| – | – | ﹤0.01% | 7419 |
|
|
2025
Q1 | $687 | Hold |
26
| – | – | ﹤0.01% | 7334 |
|
|
2024
Q4 | $853 | Hold |
26
| – | – | ﹤0.01% | 7294 |
|
|
2024
Q3 | $880 | Hold |
26
| – | – | ﹤0.01% | 7238 |
|
|
2024
Q2 | $709 | Hold |
26
| – | – | ﹤0.01% | 7193 |
|
|
2024
Q1 | $1.34K | Hold |
26
| – | – | ﹤0.01% | 7138 |
|
|
2023
Q4 | $1.54K | Buy |
26
+3
| +13% | +$206 | ﹤0.01% | 7079 |
|
|
2023
Q3 | $1.99K | Buy |
23
+1
| +5% | +$128 | ﹤0.01% | 7133 |
|
|
2023
Q2 | $3.08K | Sell |
22
-1
| -4% | -$173 | ﹤0.01% | 7096 |
|
|
2023
Q1 | $4.88K | Sell |
23
-5
| -18% | -$1.23K | ﹤0.01% | 7055 |
|
|
2022
Q4 | $8.34K | Buy |
28
+5
| +22% | +$3.76K | ﹤0.01% | 6997 |
|
|
2022
Q3 | $17K | Sell |
23
-10
| -30% | -$11.3K | ﹤0.01% | 6864 |
|
|
2022
Q2 | $39K | Sell |
33
-15
| -31% | -$20.6K | ﹤0.01% | 6715 |
|
|
2022
Q1 | $79K | Buy |
48
+4
| +9% | +$5.81K | ﹤0.01% | 6464 |
|
|
2021
Q4 | $103K | Sell |
44
-2
| -4% | -$4.13K | ﹤0.01% | 6420 |
|
|
2021
Q3 | $100K | Sell |
46
-6
| -12% | -$15.4K | ﹤0.01% | 6379 |
|
|
2021
Q2 | $148K | Buy |
52
+10
| +24% | +$31.1K | ﹤0.01% | 6168 |
|
|
2021
Q1 | $157K | Sell |
42
-19
| -31% | -$82.9K | ﹤0.01% | 5793 |
|
|
2020
Q4 | $171K | Buy |
61
+12
| +24% | +$145K | ﹤0.01% | 5668 |
|
|
2020
Q3 | $1.9M | Buy |
49
+45
| +1,125% | +$1.73M | ﹤0.01% | 3696 |
|
|
2020
Q2 | $94K | Buy |
+4
| New | +$64.4K | ﹤0.01% | 5432 |
|
|
2020
Q1 | – | Sell |
-1
| Closed | -$8.86K | – | 6399 |
|
|
2019
Q4 | $6K | Hold |
1
| – | – | ﹤0.01% | 6376 |
|
|
2019
Q3 | $4K | Hold |
1
| – | – | ﹤0.01% | 6402 |
|
|
2019
Q2 | $4K | Hold |
1
| – | – | ﹤0.01% | 6362 |
|
|
2019
Q1 | $3K | Buy |
+1
| New | +$5.2K | ﹤0.01% | 6409 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 6432 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 6517 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6513 |
|
|
2018
Q1 | – | Sell |
-2
| Closed | -$12.5K | – | 6505 |
|
|
2017
Q4 | $8K | Buy |
2
+1
| +100% | +$6.29K | ﹤0.01% | 6262 |
|
|
2017
Q3 | $3K | Buy |
+1
| New | +$8.2K | ﹤0.01% | 6366 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6462 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6633 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6689 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6774 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6699 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 6729 |
|
Other funds holding SCNI
AC
VF
SG
XT
HF
Morgan Stanley's SCNI Position: Q2 2026 in Review
Morgan Stanley held its Scinai Immunotherapeutics (SCNI) position steady in Q2 2026 at 6 shares worth $15. The position accounts for ﹤0.01% of the portfolio, ranked #8317.
Morgan Stanley first reported a position in SCNI in Q3 2017 and has held it in 31 quarters since. The position peaked at $1.9M in Q3 2020. 11 funds tracked by Wall St. Rank hold SCNI as of Q2 2026.
- Morgan Stanley held 6 shares of Scinai Immunotherapeutics worth $15 as of Q2 2026.
- Morgan Stanley left its Scinai Immunotherapeutics share count unchanged in Q2 2026.
- Scinai Immunotherapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8317 holding.
- Morgan Stanley first reported a position in Scinai Immunotherapeutics in Q3 2017 and has held it in 31 quarters since.
- Morgan Stanley's Scinai Immunotherapeutics position peaked at $1.9M in Q3 2020.
- 11 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.